Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...

Fourth-quarter highlightsOrders of $7.5 billion, including $3.8 billion of IET orders.RPO of $33.1 billion, including IET RPO of $30.1 ...

According to the competition’s new Swiss model, teams now compete in a round of 16, before quarter-finals, semis and a final ...

Ahead of the new year, Australia’s financial markets regulators convened a gathering of superannuation fund executives in ...

Manchester City scored three second half goals to come back from the brink of elimination and advance to the UEFA Champions ...

Manchester City flirted with a disastrous exit from the Champions League before rallying to beat Club Brugge 3-1 in a ...

Chemical manufacturer Stardust Power Inc. announced that it broke ground on its $1.2 billion lithium refinery at the ...

German owner Candler Schiffahrt has expanded its newbuilding orderbook in China to eight ships. Domestic shipyard Jiangxi New ...

Eight of the remaining hostages set to be released by Hamas in the first phase of a ceasefire agreement with Israel are dead, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.